Study S002783

A Single-center, Randomized, Double-blind, Placebo-controlled, Multiple Dose Escalating Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PB-119 Injection in Chinese Obese Subjects

ClinicalTrials.gov record

Registration

Registration: NCT06350812
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE1; PHASE2
Masking: DOUBLE
Status: COMPLETED
Enrollment: 32
Start: 2024-05-27
Primary completion: 2024-11-16
Lead sponsor: PegBio Co., Ltd.
Conditions: Obesity
Interventions: DRUG:PB-119; DRUG:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Incidence of Treatment-Emergent Adverse Events [From the first dosing (Day 1 ) of study drug until completion of the post treatment follow-up visit (24 week)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.